# A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

> **NCT05979441** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **argenx** · enrollment: 240 (estimated)

## Conditions studied

- Myositis
- Active Idiopathic Inflammatory Myopathy
- Dermatomyositis
- Polymyositis
- Immune-Mediated Necrotizing Myopathy
- Antisynthetase Syndrome

## Interventions

- **BIOLOGICAL:** Efgartigimod PH20 SC

## Key facts

- **NCT ID:** NCT05979441
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-09-12
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05979441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05979441, "A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05979441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*